P2RY12 and acute kidney injury: Currently suggested therapies include fibrinolytic drugs that could potentially prevent crystal clot formation and acute kidney injury without any changes in the crystal component, as well as anti-P2Y12-based antiplatelet therapies that can regulate thrombus stability by preventing platelet aggregation and activation [14].